Anita Rijneveld
Anita Rijneveld received her medical degree in 1997 at the University of Amsterdam in Amsterdam and in 2005 completed her training in Internal Medicine and Hematology at the Amsterdam Medical Center (AMC, currently known as Amsterdam UMC) under supervision of Prof Dr P. Speelman and Prof Dr M. van Oers.
She received her PhD degree in 2005. With her thesis about Pneumococcal pneumonia at the department of Infectious diseases, also at the AMC.
Our research
Acute lymphoblastic leukemia (ALL)
Her clinical research focusses on introduction of new concepts in first line treatment in adults with ALL (see HOVON). Translational research concerning prognostication and deciphering genetic subsets in adult ALL coupled with these trials is also her focus (together with bioinformatics). She is an active member of the European Working group of ALL (EWALL).
Hemoglobinopathies (HBP)
Dr Rijneveld is head of the center of expertise for hemoglobinopathies and local PI of numerous clinical trials. She is member of the Sickle Cell Outcome research (SCORE) consortium and Landelijke Werkgroep HBP Behandelaren (LWHB) and participates in European reference network on red blood cell disorders (ERN).
Relevant websites
- Patiëntenfolder Sikkelcentrum kinderen en volwassenen
- Sikkelcelziekte & Thalassemie Netwerk
Our team
Hemoglobinopathies (HBP)
Anita Rijneveld, hematologist
Minke Rab, hematologist
Aida Kidane Grebemeskel, PhD student
Acute lymphoblastic leukemia (ALL)
Jurjen Versluis, hematologist
Nick Wlazlo, hematologist
Vincent van der Velden, immunologist
Remco Hoogenboezem, bioinformatician
Mathijs Sanders, bioinformatician
Eske van Baalen, PhD student
Rosan Olsman, PhD student (in cooperation with immunology)
Aniko Szabo, PhD student
Key publications
Acute lymphoblastic leukemia (ALL)
van der Linde M, van Leeuwen N, Eijkenaar F, Anita Rijneveld, Pieters R, Karim-Kos HE. Effect of Treatment in a Specialized Pediatric Hemato-Oncology Setting on 5-Year Survival in Acute Lymphoblastic Leukemia: A Quasi-Experimental Study. Cancers (Basel). 2022 May 16;14(10):2451.
Anita Rijneveld, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE, Bellido M, van Gelder M, van der Velden WJFM, Selleslag D, van Lammeren-Venema D, Halkes CJM, Fijnheer R, Havelange V, van Sluis GL, Legdeur MC, Deeren D, Gadisseur A, Sinnige HAM, Breems DA, Jaspers A, Legrand O, Terpstra WE, Boersma RS, Mazure D, Triffet A, Tick LW, Beel K, Maertens JA, Beverloo HB, Bakkus M, Homburg CHE, de Haas V, van der Velden VHJ, Cornelissen JJ; Dutch-Belgian HOVON Cooperative group. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial. Blood Adv. 2022 Feb 22;6(4):1115-1125.
Burgers VWG, van der Graaf WTA, van der Meer DJ, McCabe MG, Anita Rijneveld, van den Bent MJ, Husson O. Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The "New" Lost Tribe. J Natl Compr Canc Netw. 2021 Mar 2;19(3):240-246.
van der Meer DJ, Karim-Kos HE, van der Mark M, Aben KKH, Bijlsma RM, Anita Rijneveld, van der Graaf WTA, Husson O. Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15-39 Years): A Population-Based Study in The Netherlands 1990-2016. Cancers (Basel). 2020 Nov 18.
Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, Cornelissen JJ, Doubek M, Esteve J, Fielding A, Foa R, Gorin NC, Gökbuget N, Hallböök H, Hoelzer D, Paravichnikova E, Ribera JM, Savani B, Anita Rijneveld, Schmid C, Wartiovaara-Kautto U, Mohty M, Nagler A, Dombret H. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019.
Hemoglobinopathies (HBP)
Van Dijck R, Goncalves Silva AM, Anita Rijneveld. Luspatercept as Potential Treatment for Congenital Sideroblastic Anemia. N Engl J Med. 2023 Apr 13;388(15):1435-1436.
Rab MAE, Kanne CK, Boisson C, Bos J, van Oirschot BA, Houwing M, Renoux C, Bartels M, Anita Rijneveld, Nur E, Cnossen MH, Joly P, Nader E, Fort R, Connes P, van Wijk R, Sheehan VA, van Beers EJ. Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease. Blood Adv. 2023 Nov 17.
van Dijk MJ, Rab MAE, van Oirschot BA, Bos J, Derichs C, Anita Rijneveld, Cnossen MH, Nur E, Biemond BJ, Bartels M, Jans JJM, van Solinge WW, Schutgens REG, van Wijk R, van Beers EJ. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. Blood Adv. 2023 Nov 7.
van Vuren A, Kerkhoffs JL, Schols S, Anita Rijneveld, Nur E, Peereboom D, Gandon Y, Welsing P, van Wijk R, Schutgens R, van Solinge W, Marx J, Leiner T, Biemond B, van Beers E. Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial. Am J Hematol. 2022 Jul;97(7):924-932.
van Dijk MJ, Rab MAE, van Oirschot BA, Bos J, Derichs C, Anita Rijneveld, Cnossen MH, Nur E, Biemond BJ, Bartels M, Jans JJM, van Solinge WW, Schutgens REG, van Wijk R, van Beers EJ. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study. Am J Hematol. 2022 Jul;97(7):E226-E229.
Houwing ME, de Pagter PJ, van Beers EJ, Biemond BJ, Rettenbacher E, Anita Rijneveld, Schols EM, Philipsen JNJ, Tamminga RYJ, van Draat KF, Nur E, Cnossen MH; SCORE Consortium Sickle cell disease: Clinical presentation and management of a global health challenge. Blood Rev. 2019 Sep;37:100580.